Koliber Biosciences
Koliber Biosciences builds predictive models and provides statistics coaching to accelerate peptide discovery and optimization for drug developers. It uses a patent-pending deep learning platform to train target-specific models of peptide activity and offers pre-trained models for solubility, serum stability, and permeability. The company combines computational biology and machine learning with wet-lab hit-discovery and lead-optimization capabilities to validate predictions. Koliber focuses on B2B scientific services and platform deployments across immunology, metabolic disease, and antimicrobials.
Koliber Biosciences
Koliber Biosciences builds predictive models and provides statistics coaching to accelerate peptide discovery and optimization for drug developers. It uses a patent-pending deep learning platform to train target-specific models of peptide activity and offers pre-trained models for solubility, serum stability, and permeability. The company combines computational biology and machine learning with wet-lab hit-discovery and lead-optimization capabilities to validate predictions. Koliber focuses on B2B scientific services and platform deployments across immunology, metabolic disease, and antimicrobials.
TL;DR
Founded: 2014
Headquarters: San Diego, CA
Focus: AI/ML-driven peptide discovery and biotech data-science services
Team size (reported): 8 employees
Funding: Grant funding from the U.S. National Science Foundation
Company Overview
Problem Domain
Peptide discovery and optimization for therapeutics across immunology, metabolic disease, and antimicrobials.
Founded
2014
Industry
Biotechnology
Funding Track Record
SBIR/STTR-style grant funding recorded in public profiles.
Recorded grant announced May 22, 2020 for an AI peptide discovery platform.
Investor Signal
“Government grant funding (U.S. National Science Foundation)”